Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. has been granted an extension by the Nasdaq Hearings Panel to remain listed on the Nasdaq Capital Market until October 31, 2024, after presenting a plan to address its non-compliance with the stockholders’ equity requirement. The company had previously fallen short of the Nasdaq’s minimum equity threshold of $2.5 million. This report will also be incorporated into the company’s existing SEC registration statements.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
